Current therapeutic strategies aim to exploit the immunostimulatory properties of CXCL10 through gene therapy, nanoparticle-based delivery or cytokine-induced upregulation to enhance immune cell infiltration, increase IFN-γ production and promote vascular normalization in the tumor microenvironment. The gene discussed is IFNG; the disease is neoplasm.